Sasha Brazhnik/iStock via Getty Images The weight loss drug sector is seeing an increasingly intensified drug development focus, causing a small player like Viking Therapeutics, Inc. (NASDAQ:VKTX) to slip. The small biotech has had some promising drug results, but the fear is the need to find a partner for GLP-1 manufacturing while additional drugs on the market could lead to pricing compression. My investment thesis is Bullish on Viking Therapeutics, especially with the gap closed down at $40.   Source ...